Whitepaper , Translational Pharmaceutics , Drug Product Optimization

Assessing the Financial Impact of Translational Pharmaceutics® - Tufts CSDD Report

30 October 2019

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

30 October 2019